Prostate cancers with MCOLN2 over-expression (mean mRNA expression z score compared to normal samples > 2, n = 73) in the MSK prostate cohort were compared with prostate cancers with lower MCOLN2 mRNA expression (n = 77) from the same cohort (Table 1). This evidence concerns the gene MCOLN2 and prostate carcinoma.